A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab (P102)
A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies
Sponsor: Leap Therapeutics, Inc.
A PHASE1 clinical study on Adenocarcinoma of the Gastroesophageal Junction and Esophageal Neoplasms, this trial is completed. The trial is conducted by Leap Therapeutics, Inc. and has accumulated 15 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Dec 2023 [monthly]
Completed PHASE1
▶ Show 10 earlier versions
-
Oct 2021 — Jun 2022 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Oct 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Leap Therapeutics, Inc.
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .